Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 91

1.

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators.

N Engl J Med. 2019 Apr 14. doi: 10.1056/NEJMoa1811744. [Epub ahead of print]

PMID:
30990260
2.

Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial.

Vaccaro O, Masulli M, Nicolucci A, Bonora E, Del Prato S, Maggioni AP, Rivellese AA, Squatrito S, Giorda CB, Sesti G, Mocarelli P, Lucisano G, Sacco M, Signorini S, Cappellini F, Perriello G, Babini AC, Lapolla A, Gregori G, Giordano C, Corsi L, Buzzetti R, Clemente G, Di Cianni G, Iannarelli R, Cordera R, La Macchia O, Zamboni C, Scaranna C, Boemi M, Iovine C, Lauro D, Leotta S, Dall'Aglio E, Cannarsa E, Tonutti L, Pugliese G, Bossi AC, Anichini R, Dotta F, Di Benedetto A, Citro G, Antenucci D, Ricci L, Giorgino F, Santini C, Gnasso A, De Cosmo S, Zavaroni D, Vedovato M, Consoli A, Calabrese M, di Bartolo P, Fornengo P, Riccardi G; Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) study group; Italian Diabetes Society.

Lancet Diabetes Endocrinol. 2017 Nov;5(11):887-897. doi: 10.1016/S2213-8587(17)30317-0. Epub 2017 Sep 13. Erratum in: Lancet Diabetes Endocrinol. 2017 Nov;5(11):e7.

PMID:
28917544
3.

Dietary intake and major food sources of polyphenols in people with type 2 diabetes: The TOSCA.IT Study.

Vitale M, Masulli M, Rivellese AA, Bonora E, Cappellini F, Nicolucci A, Squatrito S, Antenucci D, Barrea A, Bianchi C, Bianchini F, Fontana L, Fornengo P, Giorgino F, Gnasso A, Mannucci E, Mazzotti A, Nappo R, Palena AP, Pata P, Perriello G, Potenziani S, Radin R, Ricci L, Romeo F, Santini C, Scarponi M, Serra R, Timi A, Turco AA, Vedovato M, Zavaroni D, Grioni S, Riccardi G, Vaccaro O; TOSCA.IT Study Group.

Eur J Nutr. 2018 Mar;57(2):679-688. doi: 10.1007/s00394-016-1355-1. Epub 2016 Dec 21.

PMID:
28004268
4.

Canagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 Diabetes.

Qiu R, Balis D, Capuano G, Xie J, Meininger G.

Diabetes Ther. 2016 Dec;7(4):659-678. Epub 2016 Oct 12. Review.

5.

Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naïve Type 2 Diabetes.

Rosenstock J, Chuck L, González-Ortiz M, Merton K, Craig J, Capuano G, Qiu R.

Diabetes Care. 2016 Mar;39(3):353-62. doi: 10.2337/dc15-1736. Epub 2016 Jan 19.

PMID:
26786577
6.

Apparent subadditivity of the efficacy of initial combination treatments for type 2 diabetes is largely explained by the impact of baseline HbA1c on efficacy.

Polidori D, Capuano G, Qiu R.

Diabetes Obes Metab. 2016 Apr;18(4):348-54. doi: 10.1111/dom.12615. Epub 2016 Jan 25.

7.

Center-Related Determinants of VKA Anticoagulation Quality: A Prospective, Multicenter Evaluation.

Tosetto A, Manotti C, Marongiu F; Italian Federation of Anticoagulation Clinics (FCSA) clinical quality study group.

PLoS One. 2015 Dec 4;10(12):e0144314. doi: 10.1371/journal.pone.0144314. eCollection 2015.

8.

Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes.

Fulcher G, Matthews DR, Perkovic V, de Zeeuw D, Mahaffey KW, Mathieu C, Woo V, Wysham C, Capuano G, Desai M, Shaw W, Vercruysse F, Meininger G, Neal B; CANVAS trial collaborative group.

Diabetes Obes Metab. 2016 Jan;18(1):82-91. doi: 10.1111/dom.12589. Epub 2015 Dec 8.

PMID:
26450639
9.

Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study.

Barni S, Maiello E, Di Maio M, Ardizzoni A, Cappuzzo F, Maranzano E, Novello S, Bennati C, Ori A, Rizzoli S, Crinò L; RIGHT-3 study group.

Lung Cancer. 2015 Nov;90(2):234-42. doi: 10.1016/j.lungcan.2015.08.005. Epub 2015 Aug 19.

10.

Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial.

Fulcher G, Matthews DR, Perkovic V, de Zeeuw D, Mahaffey KW, Weiss R, Rosenstock J, Capuano G, Desai M, Shaw W, Vercruysse F, Meininger G, Neal B.

Diabetes Ther. 2015 Sep;6(3):289-302. doi: 10.1007/s13300-015-0117-z. Epub 2015 Jun 17.

11.

Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes.

Neal B, Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Ways K, Desai M, Shaw W, Capuano G, Alba M, Jiang J, Vercruysse F, Meininger G, Matthews D; CANVAS Trial Collaborative Group.

Diabetes Care. 2015 Mar;38(3):403-11. doi: 10.2337/dc14-1237. Epub 2014 Dec 2.

PMID:
25468945
12.

High GADA titer increases the risk of insulin requirement in LADA patients: a 7-year follow-up (NIRAD study 7).

Zampetti S, Campagna G, Tiberti C, Songini M, Arpi ML, De Simone G, Cossu E, Cocco L, Osborn J, Bosi E, Giorgino F, Spoletini M, Buzzetti R; NIRAD Study Group.

Eur J Endocrinol. 2014 Dec;171(6):697-704. doi: 10.1530/EJE-14-0342. Epub 2014 Sep 11.

PMID:
25213702
13.

Efficacy and safety of twice-daily treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, added on to metformin monotherapy in patients with type 2 diabetes mellitus.

Qiu R, Capuano G, Meininger G.

J Clin Transl Endocrinol. 2014 May 5;1(2):54-60. doi: 10.1016/j.jcte.2014.04.001. eCollection 2014 Jun.

14.

Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies.

Nyirjesy P, Sobel JD, Fung A, Mayer C, Capuano G, Ways K, Usiskin K.

Curr Med Res Opin. 2014 Jun;30(6):1109-19. doi: 10.1185/03007995.2014.890925. Epub 2014 Feb 21.

PMID:
24517339
15.

Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor.

Nicolle LE, Capuano G, Fung A, Usiskin K.

Postgrad Med. 2014 Jan;126(1):7-17. doi: 10.3810/pgm.2014.01.2720.

PMID:
24393747
16.

Different insight into amphiphilic PEG-PLA copolymers: influence of macromolecular architecture on the micelle formation and cellular uptake.

Garofalo C, Capuano G, Sottile R, Tallerico R, Adami R, Reverchon E, Carbone E, Izzo L, Pappalardo D.

Biomacromolecules. 2014 Jan 13;15(1):403-15. doi: 10.1021/bm401812r. Epub 2013 Dec 23.

PMID:
24328043
17.

Intra-prosthetic breast MR virtual navigation: a preliminary study for a new evaluation of silicone breast implants.

Moschetta M, Telegrafo M, Capuano G, Rella L, Scardapane A, Angelelli G, Stabile Ianora AA.

Magn Reson Imaging. 2013 Oct;31(8):1292-7. doi: 10.1016/j.mri.2013.05.004. Epub 2013 Jun 21.

PMID:
23791545
18.

Liver abscess and pseudotumoral gastric lesion caused by chicken bone perforation: laparoscopic management.

Ricci G, Campisi N, Capuano G, De Vido L, Lazzaro L, Simonatto G, Termini B, Turriziani V, Fidanza F.

Case Rep Surg. 2012;2012:791857. doi: 10.1155/2012/791857. Epub 2012 Nov 6.

19.

Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial.

Vaccaro O, Masulli M, Bonora E, Del Prato S, Giorda CB, Maggioni AP, Mocarelli P, Nicolucci A, Rivellese AA, Squatrito S, Riccardi G; TOSCA.IT study group (Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents. Intervention Trial).

Nutr Metab Cardiovasc Dis. 2012 Nov;22(11):997-1006. doi: 10.1016/j.numecd.2012.09.003. Epub 2012 Oct 11.

PMID:
23063367
20.

GADA titer-related risk for organ-specific autoimmunity in LADA subjects subdivided according to gender (NIRAD study 6).

Zampetti S, Capizzi M, Spoletini M, Campagna G, Leto G, Cipolloni L, Tiberti C, Bosi E, Falorni A, Buzzetti R; NIRAD Study Group.

J Clin Endocrinol Metab. 2012 Oct;97(10):3759-65. doi: 10.1210/jc.2012-2037. Epub 2012 Aug 3.

PMID:
22865904

Supplemental Content

Loading ...
Support Center